Table 1.
Patient and tumor characteristics of the selected samples.
| Characteristic | Number of patients |
|||
|---|---|---|---|---|
| Normal |
Primary |
Resistant |
Metastasis |
|
| 4 | 4 | 4 | 3 | |
| Treatment type | ||||
| Untreated | 3 | 4 | 0 | 2 |
| Bicalutamide/cyproteron acetate | 1 | 0 | 0 | 0 |
| Bicalutamide/LHRH analogue | 0 | 0 | 1 | 0 |
| Cyproteron acetate + LHRH analogue | 0 | 0 | 1 | 0 |
| LHRH analogue | 0 | 0 | 2 | 0 |
| LHRH analogue/Cyproteron Acetate | 0 | 0 | 0 | 1 |
| Gleason score | ||||
| 6 | 1 | 0 | 0 | 0 |
| 7 | 2 | 2 | 0 | 0 |
| 8 | 0 | 0 | 1 | 1 |
| 9 | 1 | 2 | 0 | 0 |
| 10 | 0 | 0 | 3 | 2 |
| Initial PSA (ng/ml) | ||||
| Mean | 8.7 | 19.6 | 149.5 | 135.5 |
| Range | 5.3–13.0 | 8.5–38.0 | 6.5–511.0 | 17.0–254.0 |